Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Aspirin + Rintatolimod |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Aspirin | Durlaza | Acetylsalicylic acid | ||
Rintatolimod | Ampligen|Atvogen|Poly(I).Poly(c12,U) | Rintatolimod (Ampligen) is a synthetic dsRNA molecule that activates TLR3 and other interferon-induced proteins, which may result in increased anti-tumor immune response (PMID: 27045557, PMID: 19200817). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03899987 | Phase II | Aspirin + Rintatolimod Aspirin + Interferon alpha-2b + Rintatolimod | Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery | Suspended | USA | 0 |